Chinen Takashi

写真a

Title

Special Lecturer
To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Hospital   Special Lecturer  

To the head of this page.▲

Published Papers 【 display / non-display 】

  • Factors associated with the cancer survivorship care practices of primary care physicians: A cross‐sectional questionnaire study in Japan

    Akihiro Nishi, Hiroki Matsui, Takashi Chinen, Sachi Takaoka, Takuji Seo, Satoshi Kanke, Teruhisa Azuma

    Journal of General and Family Medicine     2025.09 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Delayed Use of ChatGPT by Japanese Doctors Due to Limited English Language Proficiency: A Survey-Based Study in Japan.

    Kuribayashi T, Chinen T, Nagai S, Shigeta K, Fujirai Y, Uda H

    Cureus   17 ( 9 ) e91443   2025.09 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases.

    Sho Sato, Takashi Suzuki, Takashi Chinen, Hironori Yamaguchi, Yusuke Suzuki, Nobukazu Hokamura, Zenichiro Saze, Koji Kono, Keita Takahashi, Fumiaki Yano, Tsutomu Sato, Takashi Kosaka, Itaru Endo, Yasushi Ichikawa, Yutaka Miyawaki, Hiroshi Sato, Hideaki Shimada

    Journal of gastroenterology     2024.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    BACKGROUND: The real-world efficacy, prognostic factors, and adverse events of second-line nivolumab monotherapy and subsequent third-line therapy for unresectable or metastatic esophageal cancer have not been fully evaluated. METHODS: This multi-institutional retrospective cohort study evaluated 184 consecutive patients treated with second-line nivolumab monotherapy for esophageal cancer between March 2021 and December 2022. We assessed tumor response, adverse events, long-term survival, and prognostic factors. RESULTS: Among 128 patients with measurable lesions, the response rate was 23% and the disease control rate for all enrolled patients was 45%. The incidence of grade 3 or higher adverse events was 14%, but no treatment-related deaths presented. Median progression-free survival was 5.1 months and overall survival was 14 months, respectively. C-reactive protein level and performance status were identified as significant prognostic factors of overall survival through Cox proportional hazards analysis. The group with two favorable prognostic factors showed better overall survival than the groups with either one or zero prognostic factors (median overall survival: 22, 15, and 4.4 months, respectively). Among 69 patients who received third-line taxane anticancer agents, the progression-free survival was 6.7 months. CONCLUSIONS: Our study demonstrated that the real-world outcomes of second-line nivolumab monotherapy were comparable to those of previous randomized clinical trials in terms of tumor response, safety, and long-term survival. Furthermore, a good performance status and low C-reactive protein levels may identify patients who are likely to benefit from therapy. Third-line chemotherapy after nivolumab treatment may have an enhanced effect; however, further prospective studies are required to confirm this finding.

    • Access this article
      DOI
    • Search related information
      PubMed

  • Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy for Patients with Massive Malignant Ascites Secondary to Pancreatic Cancer: A Report of Two Patients.

    Yoshiyuki Meguro, Hironori Yamaguchi, Hideki Sasanuma, Kentaro Shimodaira, Yuichi Aoki, Takashi Chinen, Kazue Morishima, Hideyo Miyato, Atsushi Miki, Kazuhiro Endo, Alan Kawarai Lefor, Joji Kitayama, Naohiro Sata

    Internal medicine (Tokyo, Japan)   63 ( 14 ) 2015 - 2021   2024.07 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    The prognosis of patients with peritoneal metastases from pancreatic cancer is poor, largely due to massive ascites, which precludes systemic treatment. Two patients with a poor performance status and malignant ascites were treated with cell-free and concentrated ascites reinfusion therapy followed by combined chemotherapy with intraperitoneal paclitaxel, intravenous gemcitabine, and nab-paclitaxel. These patients achieved a survival of 19 and 36 weeks with a relatively good quality of life. Combined intraperitoneal paclitaxel and systemic chemotherapy may provide effective palliative management for some patients with peritoneal metastases from pancreatic cancer.

  • The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study.

    Sho Sato, Takashi Ssuzuki, Takashi Chinen, Hironori Yamaguchi, Yusuke Suzuki, Nobukazu Hokamura, Zenichiro Saze, Koji Kono, Keita Takahashi, Fumiaki Yano, Chikara Kunisaki, Takashi Kosaka, Itaru Endo, Yasushi Ichikawa, Yutaka Miyawaki, Hiroshi Sato, Hideaki Shimada

    International journal of clinical oncology   29 ( 7 ) 994 - 1001   2024.07 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    BACKGROUND: The real-world efficacy, feasibility, and prognostic factors of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer are not fully established. METHODS: This multi-institutional retrospective cohort study evaluated 71 consecutive patients treated with immune-checkpoint inhibitor combination therapy for esophageal cancer between March 2021 and December 2022. We assessed tumor response, safety, and long-term survival. RESULTS: In patients with measurable lesions, the response rate was 58%, and the disease control rate for all enrolled patients was 80%. Five patients (7.0%) underwent successful conversion surgery. Grade 3 or higher immune-related adverse events occurred in 13% of patients, and one patient (1.4%) died due to cholangitis. Median progression-free survival was 9.7 (95% confidence interval: 6.5-not reached). C-reactive protein levels and performance status were identified as significant predictors of progression-free survival through Cox proportional hazards analysis. CONCLUSIONS: Immune-checkpoint inhibitor combination therapy for esophageal cancer demonstrated comparable tumor response, safety, and long-term survival to previous randomized clinical trials. Patients with good performance status and low C-reactive protein levels may be suitable candidates for this treatment.

    • Access this article
      DOI
    • Search related information
      PubMed

display all >>

To the head of this page.▲

Presentations 【 display / non-display 】

  • 胃癌腹膜播種に対するパクリタキセル腹腔内投与併用化学療法

    山口 博紀, 風當 ゆりえ, 加賀谷 丈紘, 金丸 理人, 高橋 和也, 松本 志郎, 倉科 憲太郎, 齋藤 心, 知念 崇, 宮戸 秀世, 大澤 英之, 細谷 好則, 北山 丈二, 佐田 尚宏

    日本癌治療学会学術集会抄録集  1900.01  -  1900.01 

To the head of this page.▲